Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase II/III Acne Scar Study

Thursday, October 23, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

EXTON, Pa., Oct. 21 Isolagen(TM), Inc.(Amex: ILE) announced today that all injections have been completed in thePhase II/III Study IT-A-008 investigating Isolagen Therapy(TM) for thetreatment of moderate to severe facial acne scars. Further, approximatelyhalf of all of the study participants have completed the final observationvisit. Isolagen anticipates the acne study will conclude in the first quarterof 2009.

"The second half of 2008 has been very productive for Isolagen as wecontinue to deliver on our clinical milestones on time and with positiveresults," said Declan Daly, Chief Executive Officer of Isolagen. "Wepreviously announced positive top-line results from our pivotal Phase IIIwrinkle study and positive results from our open label Phase II study of thefull face. We are very excited that our acne program is progressing on timeand we believe the dermatology community will be very interested in this dataearly next year because of the unmet need for a minimally invasive acne scartreatment. Our current priority is to gain additional funding and secure astrategic partner to help us deliver on the exciting clinical promise of theIsolagen therapy in all of these areas."

About the Isolagen Process(TM) and Isolagen Therapy(TM)

The Isolagen Process(TM) is an innovative cellular processing system whichcreates a natural, living cell therapy. By multiplying a patient's owncollagen-producing cells or fibroblasts into tens of millions of new cells, apersonalized treatment is created which is then returned to the patient'sskin. This treatment, known as the Isolagen Therapy(TM), is designed toimprove skin damage caused by the normal effects of aging, sun damage, acneand burns.

About Isolagen, Inc.

Isolagen(TM), Inc. (Amex: ILE) is an aesthetic and therapeutic companycommitted to developing and commercializing scientific advances and innovativetechnologies. The company's technology platform includes the IsolagenProcess(TM), a cell processing system for skin and tissue rejuvenation whichis currently in clinical development for a broad range of aesthetic andtherapeutic applications including wrinkles, acne scars, burns and periodontaldisease. Isolagen also commercializes a scientifically-advanced line ofskincare systems through its majority-owned subsidiary, Agera(R) Laboratories,Inc. For additional information, please visit

Isolagen Forward Looking Statements

All statements in this news release that are not based on historical factare "forward-looking statements" within the meaning of the Private SecuritiesLitigation Reform Act of 1995 and the provisions of Section 27A of theSecurities Act of 1933, as amended, and Section 21E of the Securities ExchangeAct of 1934, as amended. Forward-looking statements in this press release,include, without limitation, the timely completion of the overall acne study,the timely completion of the Company's Phase III wrinkle study, and theCompany's ability to raise additional funding, whether through strategicpartners, financing, or otherwise. While management has based anyforward-looking statements contained herein on its current expectations, theinformation on which such expectations were based may change. Theseforward-looking statements rely on a number of assumptions concerning futureevents and are subject to a number of risks, uncertainties, and other factors,many of which are outside of our control, that could cause actual results tomaterially differ from such statements. Such risks, uncertainties, and otherfactors include, but are not necessarily limited to, those set forth underItem 1A "Risk Factors" in the Company's Annual Report on Form 10-K for theyear ended December 31, 2007, as updated in "Item 1A. Risk Factors" in theCompany's Quarterly Reports on Form 10-Q filed since the annual report. Weoperate in a highly competitive and rapidly changing environment, thus new orunforeseen risks may arise. Accordingly, investors should not place anyreliance on forward-looking statements as a prediction of actual results. Wedisclaim any intention to, and undertake no obligation to, update or reviseany forward-looking statements. Readers are also urged to carefully review andconsider the other various disclosures in the Company's Annual Report on Form10-K for the year ended December 31, 2007, as well as other public filingswith the SEC since such date.

SOURCE Isolagen, Inc.

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store